Sol-Gel Technologies, Ltd.

Quick facts

Marketed products

• Efudex®

Phase 3 pipeline

• Patidegib Topical Gel · Oncology
  Patidegib is a smoothened (SMO) inhibitor that blocks hedgehog signaling pathway activation, reducing abnormal cell proliferation in skin tumors.
• S5G4T-2 · Dermatology
  S5G4T-2 is a topical gel formulation of a retinoid, which works by modulating the activity of retinoic acid receptors in the skin.
• S6G5T-3 · Dermatology
  S6G5T-3 is a topical gel formulation of a proprietary molecule that targets the sebaceous glands to treat acne.
• S6G5T-8 · Ophthalmology
  S6G5T-8 is a topical ophthalmic formulation designed to treat dry eye disease by promoting tear production and reducing ocular surface inflammation.

Phase 2 pipeline

• DER 45 EV
• S6G5T-1
• S6G5T-5
• S6G5T-6
• S6G5T-7

Phase 1 pipeline

• Encapsulated Benzoyl Peroxide Cream
• Retin-A® 0.1% Cream

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sol-Gel Technologies, Ltd. portfolio CI brief
• Sol-Gel Technologies, Ltd. pipeline updates RSS